INVO Bioscience, Inc. Share Price

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:30:00 24/06/2024 BST 5-day change 1st Jan Change
0.8484 USD +1.00% Intraday chart for INVO Bioscience, Inc. -20.71% -37.16%
Sales 2022 822K 64.77M Sales 2023 3.02M 238M Capitalization 3.34M 263M
Net income 2022 -10M -788M Net income 2023 -8M -630M EV / Sales 2022 9.4 x
Net Debt 2022 2.57M 203M Net Debt 2023 8.45M 666M EV / Sales 2023 3.9 x
P/E ratio 2022
-0.47 x
P/E ratio 2023
-0.26 x
Employees 28
Yield 2022 *
-
Yield 2023
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.00%
1 week-20.71%
Current month-1.35%
1 month-4.67%
3 months-24.92%
6 months-31.02%
Current year-37.16%
More quotes
1 week
0.78
Extreme 0.782
0.94
1 month
0.72
Extreme 0.72
1.10
Current year
0.70
Extreme 0.7
3.50
1 year
0.50
Extreme 0.5
7.20
3 years
0.50
Extreme 0.5
100.00
5 years
0.50
Extreme 0.5
273.54
10 years
0.50
Extreme 0.5
953.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10/10/17
Director of Finance/CFO 56 13/06/21
Chief Tech/Sci/R&D Officer - 30/11/20
Members of the board TitleAgeSince
Director/Board Member 56 15/12/19
Director/Board Member 64 13/09/20
Corporate Secretary 55 30/09/08
More insiders
Date Price Change Volume
24/06/24 0.8484 +1.00% 69,587
21/06/24 0.84 -5.62% 129,400
20/06/24 0.89 -7.29% 97,560
18/06/24 0.96 -10.28% 146,589

Delayed Quote Nasdaq, June 24, 2024 at 09:30 pm

More quotes
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
More about the company